Mutations in any one of these three genes, HEXA, HEXB or GM2A, can cause the accumulation of the GM2 gangliosides and other terminal HexNAc-containing substrates, which make them relevant biomarkers of disease progression and treatment effects in GM2 gangliosidosis. The gene discussed is GM2A; the disease is GM2 gangliosidosis.